The long-term clinical effects of soy protein containing various amounts of isoflavones on lipoproteins, mononuclear cell LDL receptor messenger RNA concentrations, and other selected cardiovascular risk factors are not well known. Sixty-six hypercholesterolemic, free-living, postmenopausal women were investigated during a 6-mo parallel-group, doubleblind trial with 3 interventions. After a control period of 14 d, all subjects were randomly assigned to 1 of 3 dietary groups (all with 40 g protein): a National Cholesterol Education Program (NCEP)
INTRODUCTION
Dietary proteins have long been understood to be involved in the development of coronary artery disease (CAD), and, in the past 20 y, research has shown that plasma cholesterol decreases when soy protein is substituted for animal protein in the diets of hypercholesterolemic individuals (1, 2) . Some investigations have reported up to a 35% reduction in total plasma cholesterol (3), whereas others have reported no change or even slight increases (4, 5) . There are many different soy products suitable for human consumption and, depending on the range of conditions under which they were manufactured, they contain markedly different components. When equivalent amounts of protein are fed, isolated soy protein results in larger depressions in plasma lipids than does defatted soy flour (6) . Furthermore, cholesterol concentrations are higher when amino acids patterned after soy are fed than when intact soy proteins are fed, although cholesterol concentrations are reduced compared with when amino acids patterned after casein or intact casein are fed (7) . Therefore, the hypocholesterolemic effects seen with feeding isolated soy protein may be due, in part, to the biologically active compounds found in soy other than the protein itself, and the wide variation in responsiveness in humans may be due in part to the removal of one or more of these active compounds during the manufacturing process.
Animal studies have indicated that serum lipid profiles are influenced by components of an ethanol extract of soy (7) (8) (9) (10) . Isoflavones are one group of biologically active compounds known to be removed from soy during organic extraction (11) . The isoflavones are structurally similar to estrogen and bind to the estrogen receptor, eliciting a weak estrogenic response (12) . Because of this, the soybean isoflavones have been implicated in the reduction of cardiovascular disease (11) .
Women can potentially lower their risk of CAD with estrogen replacement therapy. Decreases in total and LDL cholesterol as Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women well as increases in HDL cholesterol are routinely noted in postmenopausal women receiving estrogen replacement therapy (13, 14) . The mechanism by which estrogen alters plasma lipoprotein concentrations is unclear, but it is known that reduced LDL-cholesterol concentrations associated with estrogen intake are a direct result of increased LDL receptor activity (15) . Interestingly, an increase in LDL receptor activity has also been noted in animals and humans fed soybean protein-based diets (16, 17) .
Because of the antiatherogenic effects of estrogens and because soy products contain various amounts of isoflavones (depending on the manner of processing), we were interested in investigating the possible role of isoflavones in lipid metabolism. Data reported thus far on the effects of soy protein on lipid and lipoprotein concentrations have been derived from soy intervention studies involving men only or a combination of men and women. Few studies have evaluated women specifically, and postmenopausal women have never been distinguished from premenopausal women even though CAD is the leading cause of morbidity and mortality in older women. In addition, studies on the short-term effects (≤ 4 wk) of consuming soy protein are numerous although little is known about how lipid metabolism is affected with longerterm intake of soy protein. Therefore, this study was designed to investigate the effect of soy protein and isoflavones on blood lipid profiles and mononuclear cell LDL receptor messenger RNA (mRNA) in postmenopausal women over a 6-mo feeding period.
SUBJECTS AND METHODS

Subjects
Postmenopausal women (Table 1) were recruited from the vicinity of Champaign-Urbana, IL, through flyers, letters, and physician referrals. These subjects were studied during 3 separate, 24-wk cohort studies: cohort 1 during summer and fall of 1994 (n = 28), cohort 2 during spring and summer of 1995 (n = 28), and cohort 3 during summer and fall of 1995 (n = 25). Subject selection excluded those receiving hormone replacement therapy or any other medications known to lower plasma cholesterol, those with a history of diabetes mellitus or thyroid disease, those with chronic illness that could affect lipid measurements or limit the individual's ability to participate in the study, and those with allergy to soybean protein. Inclusion criteria were the completion of menopause with ≥ 1 y since the last menstrual period and a total plasma cholesterol concentration between 6.2 and 7.8 mmol/L. None of the subjects reported clinical evidence of renal, liver, or thyroid dysfunction. The project was approved by the Institutional Review Board at the University of Illinois at Urbana-Champaign. A thorough explanation of the experimental protocol was given and informed consent was obtained from each subject before entry.
Of the 134 women screened, 81 women aged 49-83 y gave their informed consent and 74 subjects completed the study. Seven withdrew from the study durings weeks 1-4 for various reasons: 1 moved to another state, 3 withdrew because of medical problems unrelated to soy product consumption, and 3 withdrew because they were unable to comply with the study protocol. Eight subjects who completed the protocol were excluded from the statistical analyses: 2 subjects gained or lost ≥ 3 kg during the study, 1 subject had a baseline cholesterol concentration of 4.7 mmol/L, 1 subject had a baseline cholesterol concentration of 9.8 mmol/L, and 4 subjects failed to adhere to the low-fat, low-cholesterol basal diet as assessed by the investigators and a registered dietitian. Therefore, statistical analyses were performed on data from 66 subjects from the 3 cohorts. Data from the cohorts were pooled for the final analyses.
Diet
Two weeks before the study, each subject completed a 2-d dietary intake record and was interviewed by a registered dietitian so that her daily energy requirement could be calculated for a basal low-fat, low-cholesterol National Cholesterol Education Program (NCEP) Step 1 diet (18) . Each subject received a booklet published by the American Heart Association (19) containing a long list of foods along with a calculated "fat gram prescription," which complied with the criteria listed above for the basal diet.
Study design
All subjects followed the basal diet for ≥ 14 d. After this, baseline blood samples were drawn on 2 separate days, and subjects were randomly assigned to 1 of the 3 dietary treatment groups. Note that most subjects were already consuming diets similar to the NCEP Step 1 diet before enrolling in the study. All Table 2 ). The isolated soy proteins were fortified with calcium to provide 800-900 mg Ca/d as calcium phosphate. This amount was consistent with the amount of calcium provided by the dairy component for the group consuming the CNFDM treatment. Subjects were blinded to the source of test protein during the trial period. Investigators involved in the production of test 6.6 ± 0.9 6.5 ± 0.9 6.3 ± 0.7 (5.5-8.6) (5.6-9.1)
1 x -± SD; range in parentheses. ISP56, isolated soy protein with 56 mg total aglycone isoflavones/40 g protein; ISP90, isolated soy protein with 90 mg total aglycone isoflavones/40 g protein; CNFDM, casein and nonfat dry milk. There were no significant differences between groups for any characteristic listed.
protein-containing products were aware of dietary treatment codes; however, laboratory personnel and individuals analyzing data were blinded to the treatments. A combination of products was consumed by subjects to provide 40 g test protein daily. The Department of Food Science and Human Nutrition at the University of Illinois developed recipes that incorporated the CNFDM and soy isolates into baked products. Ready-to-mix beverages and soups containing isolated soy protein or CNFDM were also used (provided by Protein Technologies International, St Louis). Subjects were provided with a protein, fat, and energy breakdown for the test protein items. All baked products were prepared by a professional baker in the University of Illinois Quantity Foods Laboratory and were individually packaged and distributed to subjects during a breakfast held at the study site 3 d/wk. Cereals, fruit, tea, coffee, juice, and lowenergy carbonated beverages were also offered during the breakfast service.
Throughout the study, all subjects were instructed by a registered dietitian about maintenance of body weight, physical activity, dietary requirements, and acceptable food and beverage intake. Additionally, every 4 wk, 3 d were chosen at random to include 2 weekdays and 1 weekend day when subjects were asked to complete 3-d dietary intake records. Actual daily nutrient intakes were analyzed by using a nutritional analysis software program (NUTRITIONIST IV, version 3.0; N-Squared Computing, Salem Park, OR). Body weight was measured weekly by using a balance-beam scale (Detecto Physician's scale; Detecto Scale Company, Webb City, MO), which was calibrated weekly. Assessment of daily physical activity was made by using activity reports that subjects submitted with their 3-d food intake records. Subjects used assigned numbers to rate different levels of physical activity and these values were tabulated for statistical analyses (20) .
Sample collection
On 2 separate days at the end of the 2-wk adaptation period (baseline) and every 6 wk for the duration of the 24-wk study, blood samples were collected between 0600 and 0900, after a 12-h fast, from either the antecubital or dorsal hand vein of each subject into tubes containing heparin, EDTA, or no anticoagulant. Plasma was separated by centrifugation at 1190 ϫ g for 15 min at 4 ЊC. HDL and HDL 3 lipoprotein fractions were separated immediately by heparin-manganese precipitation (21) 
LDL receptor mRNA analysis
Mononuclear cells were isolated as described by Lovati et al (16) . Mononuclear cell RNA was isolated from 38 of the 66 subjects (n = 15 for ISP56, n = 12 for ISP90, and n = 11 for CNFDM) at baseline and after 12 and 24 wk of the study. Total cellular RNA was prepared from mononuclear cells by using the single-step acid guanidinium thiocyanate-phenol-chloroform method (22) . Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantitate LDL receptor mRNA concentrations (23) . One microgram of total cellular RNA from each sample was reverse-transcribed along with 2 ϫ 10 5 copies of internal standard template pAW109 RNA (Perkin-Elmer, Norwalk, CT) in a 20-L volume. As an internal standard, pAW109 RNA was coamplified in RT-PCR reactions with sample RNAs and primers specific to the LDL receptor complementary DNA. The PCR products for the pAW109 RNA and LDL receptor mRNA were 301 and 258 base pairs, respectively. PCR was performed with a final concentration of 0.25 mmol dNTPs/L, 0.15 mmol/L each of 5Ј and 3Ј primers, 4 mmol MgCl 2 /L, and 2.5 units of Taq polymerase in a final volume of 100 L. The PCR process included 25 cycles at 95 ЊC for 1 min followed by 60 ЊC for 1 min. Twenty-five microliters of each PCR reaction mixture was size-fractionated by electrophoresis on a 2%-agarose gel and then transferred to a positively charged nylon membrane. A 32 P end-labeled primer was used to hybridize to the internal standard and sample PCR products. Hybridization was visualized and quantitated by using autoradiography (PhosphorImager; Molecular Dynamics, Sunnyvale, CA). The concentration of LDL receptor mRNA (copies of LDL receptor mRNA/mg total RNA) was calculated based on the relative amount of hybridization to the pAW109 RNA internal standard. 
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Statistical analysis
The effects of dietary supplementation on various outcomes were evaluated by using multiple linear regression analyses. Treatment effects were indicated by using 2 dummy-coded variables, one contrasting the ISP90 diet with the CNFDM diet, and the second contrasting the ISP56 diet with the CNFDM diet. The outcome variables analyzed were various measures of plasma cholesterol: total, non-HDL, HDL, HDL 2 , HDL 3 , and the ratio of total to HDL. For each variable, the outcome evaluated was the subject's change from baseline. In addition, in each analysis, the baseline value of the outcome variable was included in the model as a covariate. Including the baseline value as a covariate adjusts statistically for baseline differences between groups. Treatmentby-covariate interaction effects were tested as outlined in Weigel and Narvaez (24) . This allows for determination of the effect of baseline values in the response to treatment. If there were no significant interaction effects, the interaction terms were removed from the model. The regression model assumptions of normality and homogeneity of variance of residuals were evaluated by inspection of the plots of residuals versus predicted values.
The temporal onset of effects was detected sequentially by testing for the presence of significant treatment effects first at 24 wk after treatment and then proceeding backwards to test for significant effects at 18, 12, and 6 wk, proceeding to the earlier time in sequence only when significant effects had been identified at each later time period. In addition, differences between groups in nutrient intake, physical activity, and body mass index (wt/ht 2 ) at each time point were compared by using one-way analysis of variance. Changes from baseline within each group were evaluated by using paired t tests. In addition, analysis of variance was performed on all baseline measurements and measurable subject characteristics to assess equality between groups. All statistical procedures were conducted by using the Statistical Analysis System (SAS Institute Inc, Cary, NC). An ␣ level of 0.05 was used in all statistical tests.
RESULTS
Dietary intake, body mass index, and physical activity
Consumption of the test protein-containing items was well accepted by the subjects in all 3 groups. This was thought to be because of the wide array of palatable baked products, soups, and beverages that were offered to subjects. The daily energy intake in all 3 groups was similar. At baseline, the average daily energy intake ranged from 6725 ± 1805 to 6986 ± 1636 kJ (x -± SD; n = 66). At 24 wk, the average daily energy intake ranged from 6747 ± 1609 to 7149 ± 1157 kJ (n = 66). One-way analysis of variance indicated there were no significant differences in dietary intake for any of the selected nutrients except for protein. Protein intake was significantly greater at 24 wk than at baseline in all 3 groups (P < 0.05, paired t test). The average daily intake of cholesterol was always < 300 mg. There were no significant differences in body mass index at baseline between groups nor were there changes in body mass index or physical activity between the 3 dietary groups during the intervention period.
Plasma lipids
No significant changes in plasma total cholesterol were observed in any of the treatment groups over the 24-wk treatment period ( Table 3) . However, both the ISP56 and ISP90 groups had greater decreases in non-HDL cholesterol from baseline than did the CNFDM group (P < 0.05). In addition, HDL cholesterol was greater in subjects consuming ISP56 and ISP90 than in those consuming CNFDM at 18 and 24 wk (P < 0.05). Compared with baseline, at the termination of the study there was a 5.2% increase in HDL cholesterol with the ISP56 diet and a 3.6% increase with the ISP90 diet compared with a 4.1% decrease with the CNFDM diet. No significant differences were observed in the concentrations of HDL 2 cholesterol. Mean change from baseline to 18 and 24 wk for the HDL 3 -cholesterol fraction was significantly greater in the ISP56 group than in the CNFDM group. There was a decrease in the ratio of total to HDL cholesterol at 24 wk with the ISP56 diet (10%) and the ISP90 diet (8%) compared with an increase in this ratio (3%) with the CNFDM diet (P < 0.05). Total plasma triacylglycerol concentrations did not change significantly during the study. Plasma concentrations of apo A-I and B did not change significantly (data not shown). Mean apo A-I concentrations ranged from 1.47 ± 0.17 to 1.50 ± 0.22 g/L at baseline and at 24 wk they ranged from 1.48 ± 0.16 to 1.54 ± 0.24 g/L (n = 66). Baseline mean apo B concentrations ranged from 1.47 ± 0.39 to 1.50 ± 0.34 g/L at baseline and at 24 wk they ranged from 1.41 ± 0.31 to 1.46 ± 0.44 g/L (n = 66).
LDL receptor mRNA
LDL receptor mRNA concentrations are shown in Table 4 . Compared with baseline, LDL receptor mRNA concentration at 24 wk was greater in both the ISP56 and ISP90 groups (by 27% and 75%, respectively), and reduced in the CNFDM group (by 26%; P < 0.01). No significant differences among the groups in change since baseline were detected at 12 wk.
There were no significant differences between groups at baseline for any of the outcome measurements or measurable subject characteristics. For all regression analyses performed, inspection of residual plots revealed no violations of the model assumptions of normality and homogeneity of variance of residuals.
DISCUSSION
These data indicate that feeding 40 g soy protein containing different amounts of isoflavones, along with an NCEP Step 1 diet, affects plasma lipoprotein concentrations and LDL receptor mRNA in hypercholesterolemic, postmenopausal women. Lowfat, low-cholesterol diets similar to the NCEP Step 1 diet have been shown to reduce serum cholesterol concentrations in humans by as much as 14% (25) . However, the enhanced effects on plasma lipoproteins observed with the addition of soy protein to an NCEP Step 1 diet provide additional evidence that dietary protein influences the risk of CAD in humans.
Although total cholesterol concentrations did not change, significant decreases in non-HDL (LDL + VLDL) cholesterol and significant increases in HDL cholesterol were seen. This lack of effect on plasma total cholesterol of the 2 soy protein diets is not consistent with our previous studies in mildly hypercholesterolemic men (6, 26) , nor with findings from a recent meta-analysis (1) that evaluated data from 38 clinical studies, the majority of which focused on men. In 1993, we reported a 12% reduction in total cholesterol and an 11.5% reduction in LDL cholesterol with no change in HDL cholesterol when hypercholesterolemic men consumed 50 g soy protein/d (6) . Adding 25 g soy protein each day to a low-fat, low-cholesterol diet lowered plasma total cholesterol concentrations between 6% and 8% in men with hypercholesterolemia (26) . In addition, we reported that apo B decreased significantly in men consuming 50 g soy protein/d. This decline paralleled the decline of LDL cholesterol (6) . Yet, in our present study, apo B concentrations were unaffected by the diets, possibly because of the somewhat moderate decreases in the apo B-containing lipoproteins (non-HDL) or because of an effect of sex. We also noted the lack of a parallel increase in apo A-I with the increase in HDL cholesterol. Again, this may be related to the magnitude of the increase in HDL or a difference between men and women.
We did, however, observe significant increases in HDL cholesterol, as did Kurowska et al (27) in a recent report on subjects consuming soy milk. With regard to the HDL subfractions, our observation of increases in HDL-and HDL 3 -cholesterol concentrations while HDL 2 -cholesterol concentrations remained unchanged may indirectly indicate that cholesterol ester transfer protein activity is affected by soy protein. However, increases in cholesterol ester transfer protein are theoretically associated SOY PROTEIN IMPROVES BLOOD LIPIDS 549 (29) . The clinical significance of the HDL subfractions remains controversial. Estrogens are associated with increases in HDL 2 whereas alcohol intake is associated with increases in HDL 3 -both of these variables are associated with a potential decrease in cardiovascular risk (28) . The bioactive component in soy protein that mediates changes in blood lipids is not known. A variety of these compounds have been postulated (11) . Of these, there is much interest in the isoflavones and various peptides and globulins (16). Anthony et al (8, 30) and Honore et al (31) showed that washing an isolated soy protein similar to that used in the current study with alcohol eliminated the cholesterol-lowering effect, increased atherosclerotic plaque size, and resulted in vasoconstriction in response to acetylcholine. These authors attributed the effects to isoflavones. Lovati et al (16) showed that LDL receptor activity is enhanced and blood lipids are reduced by ingestion of an extract containing a 17-kDa globulin. Data from the present study in humans indicate 1 of 2 possibilities: 1) that isoflavones are not involved in the effect in humans, or 2) that the amount of isoflavones fed was at a plateau with respect to ability to influence blood lipid profiles. The latter is supported by previous work in our laboratory showing that there is a dose-response curve, for which a plateau exists, followed by a degradation of effect (9) . The former is supported by a recent letter by Sirtori et al (32) indicating that the products fed in their previous studies were devoid of isoflavones. Definitive evidence for the effect of isoflavones in humans would be best addressed in a study comparing soy proteins with and without isoflavones-neither we nor Sirtori et al have conducted such an experiment. Note, too, that saponins are capable of decreasing blood cholesterol concentrations by enhancing fecal excretion of bile (11) . Soy products do contain saponins, and these are also removed by alcohol washing.
The significant reduction observed in the current study in non-HDL cholesterol, which is predominantly LDL cholesterol (33), may be associated with enhanced activity of the LDL receptors because we found increases in mononuclear cell LDL receptor mRNA concentrations. Because the LDL receptor gene was found to be regulated similarly in blood mononuclear cells and the liver, and the concentration of the LDL receptor mRNA in mononuclear cells is comparable with that in the liver (34) , it is reasonable to postulate that soy protein, by some not yet understood mechanism, may also increase hepatic LDL receptor mRNA concentrations to enhance LDL receptor activity. Reductions in LDL-cholesterol concentrations with soy protein by way of increased LDL receptor activity in human blood monocytes was also shown by Lovati et al (16) , whereas Angelin et al (35) documented the effects of estrogen on the up-regulation of human hepatic LDL receptors. It has been suggested that changes in LDL receptor activity are produced by various peptide components found in soy protein (32) . It is also possible that nonproteinaceous components could be exerting effects; that is, isoflavones might have an estrogen-like enhancement of LDL receptor activity.
Even though total cholesterol did not change in subjects in the current study, cardiovascular risk improved with consumption of soy regardless of isoflavone content. Several clinical trials support a protective role of HDL against atherosclerosis and provide evidence that reducing LDL-cholesterol concentrations will decrease the occurrence of subsequent coronary events and CAD mortality (36, 37) . Other evidence shows that for every 0.026-mmol/L (1-mg/dL) increase in HDL cholesterol, the risk for CAD is decreased by 3% in women (33) .
Any dietary intervention to lower cardiovascular risk must be shown to maintain effects over a fairly long period of time. Our study, for the first time, shows that lipid changes that occur with soy protein are maintained over a sustained period of time. Anderson et al (1) reported that previous studies in their metaanalysis lasted an average of 4 wk, whereas Carroll (2) reported that study length varied from as little as 10 d to as long as 12 wk.
In conclusion, our findings confirm the effectiveness of dietary soy protein in decreasing LDL cholesterol and its influence on genetic signaling for LDL receptor formation in hypercholesterolemic postmenopausal women. Furthermore, these women were able to include 40 g soy protein in their diets without having to substantially alter intake of other sources of dietary protein. 
